1 min read
Meet Veristat at BIO-Europe Spring: March 23-25, 2026 - Lisbon, Portugal
🔬 Connecting with the Global Biopharma Community
Veristat is pleased to attend BIO-Europe Spring, where biotech...
Successfully transitioning from academic or bench-top production to manufacture clinical-grade material is not an easy feat. There are many factors new sponsors must consider when determining readiness to file an Investigational New Drug (IND) from a manufacturing perspective. FDA guidance for INDs for Phase 1 points out that ‘insufficient data to make an evaluation of safety is the only basis of a clinical hold based on the CMC section.’
Listen to the full episode on Veristat’s Advancing Revolutionary Therapies (ART) Podcast to learn more about the key CMC fundamentals and pitfalls of preparing for an IND.
- Manufacturing considerations when preparing for an IND
- Factors to consider when selecting a CMO for early clinical trial
- CMC fundamentals for preparing for a pre-IND FDA meeting
Meet Veristat. Learn More: Regulatory Affairs, Operations and Consulting
Get the Latest News
Categories
- Regulatory Consulting (135)
- Regulatory Submissions (128)
- Clinical Trial Regulations (119)
- COVID-19 (46)
- Strategic Consulting (38)
- Clinical Trials (33)
- Life At Veristat (21)
- Oncology (18)
- Events (16)
- Success Stories (13)
- Project Management (11)
- Clinical Operations/Monitoring (10)
- Decentralized Trials/Virtual Trials (9)
- Full-Service (9)
- Medical Writing (9)
- CMC (6)
- Data Management (5)
- Marketing Applications (5)
- Adaptive Design (4)
- Statistics and Programming (4)
- Biologics (3)
- Cell Gene and RNA (3)
- Biometrics (2)
- Natural History (2)
- Neurology/CNS (2)
- Rare Diseases (2)
- Hematology (1)
- Medical Affairs (1)
1 min read
Meet Veristat at PHUSE US Connect: Advancing Data-Driven Clinical Development
Mar 18, 2026 Veristat Events
🔬 Connecting with the Global Clinical Data and Biostatistics Community
Veristat is pleased to attend PHUSE US Connect...